Ganglioside GD2 antigen (GD2)

Ganglioside GD2 antigen is a glycosphingolipid composed of a ceramide lipid backbone and a pentasaccharide chain, including two sialic acids, that is inserted in the outer leaflet of the plasma membrane[1][2][4]. It is normally expressed at low levels in the central nervous system and peripheral nerves, but is highly upregulated on the surface of various neuroectoderm-derived tumors, notably neuroblastoma, melanoma, osteosarcoma, and small cell lung cancer, making it a well-established tumor-associated antigen and therapeutic target[1][3][5][6]. Structurally, GD2 serves roles in cell–cell adhesion, signal transduction, and modulation of the tumor microenvironment; its overexpression in tumors is implicated in proliferation, migration, and immune evasion[3][4][6]. Therapeutic monoclonal antibodies and CAR-T cells targeting GD2 have been approved or are under clinical investigation, though therapies are limited by on-target off-tumor toxicity, particularly neuropathic pain, owing to low GD2 expression in normal nerve tissues[5][6][4]. Circulating GD2 can serve both as a diagnostic and prognostic biomarker, especially in neuroblastoma[2][3]. Overall, GD2 is considered a prototypical example of a carbohydrate tumor antigen and a non-protein therapeutic target in oncology, with significant ongoing interest in developing safer targeted therapies and antibody-based regimens[3][4][6].

Other names

disialoganglioside GD2GD2 gangliosideGD2 antigen

Antibody-dependent cell-mediated cytotoxicity (ADCC), Complement-dependent cytotoxicity (CDC), Direct induction of cell death, T-cell mediated cytotoxicity (for CAR-T), Immune checkpoint inhibition